1. Home
  2. TWG vs INTS Comparison

TWG vs INTS Comparison

Compare TWG & INTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • TWG
  • INTS
  • Stock Information
  • Founded
  • TWG 2009
  • INTS 2012
  • Country
  • TWG Hong Kong
  • INTS United States
  • Employees
  • TWG N/A
  • INTS N/A
  • Industry
  • TWG
  • INTS Biotechnology: Pharmaceutical Preparations
  • Sector
  • TWG
  • INTS Health Care
  • Exchange
  • TWG NYSE
  • INTS Nasdaq
  • Market Cap
  • TWG 7.7M
  • INTS 8.7M
  • IPO Year
  • TWG 2024
  • INTS 2023
  • Fundamental
  • Price
  • TWG $0.11
  • INTS $0.46
  • Analyst Decision
  • TWG
  • INTS Strong Buy
  • Analyst Count
  • TWG 0
  • INTS 3
  • Target Price
  • TWG N/A
  • INTS $8.50
  • AVG Volume (30 Days)
  • TWG 4.2M
  • INTS 1.3M
  • Earning Date
  • TWG 02-15-2025
  • INTS 05-13-2025
  • Dividend Yield
  • TWG N/A
  • INTS N/A
  • EPS Growth
  • TWG N/A
  • INTS N/A
  • EPS
  • TWG N/A
  • INTS N/A
  • Revenue
  • TWG $4,747,580.00
  • INTS N/A
  • Revenue This Year
  • TWG N/A
  • INTS N/A
  • Revenue Next Year
  • TWG N/A
  • INTS N/A
  • P/E Ratio
  • TWG N/A
  • INTS N/A
  • Revenue Growth
  • TWG N/A
  • INTS N/A
  • 52 Week Low
  • TWG $0.10
  • INTS $0.29
  • 52 Week High
  • TWG $13.50
  • INTS $5.10
  • Technical
  • Relative Strength Index (RSI)
  • TWG N/A
  • INTS 38.44
  • Support Level
  • TWG N/A
  • INTS $0.29
  • Resistance Level
  • TWG N/A
  • INTS $0.63
  • Average True Range (ATR)
  • TWG 0.00
  • INTS 0.09
  • MACD
  • TWG 0.00
  • INTS 0.06
  • Stochastic Oscillator
  • TWG 0.00
  • INTS 50.88

About TWG TOP WEALTH GROUP HLDG LTD

Top Wealth Group Holding Ltd is as supplier of caviar and offer caviar-based gourmet products. It is specialized in supplying high quality sturgeons caviar.

About INTS Intensity Therapeutics Inc. Common stock

Intensity Therapeutics Inc is a clinical-stage biotechnology company pioneering a new immune-based approach to treat solid tumor cancers. The company leverages its DfuseRxtechnology platform to create new, proprietary drug formulations that, following direct injection, rapidly disperse throughout a tumor and diffuse therapeutic agents into cancer cells. Intensity's product candidates have the potential to induce an adaptive systemic immune response that not only attacks the injected tumor, but also non-injected tumors. Their pipeline is focused on realizing the full potential of INT230-6 in metastatic and local disease settings to help cancer patients with unmet medical need.

Share on Social Networks: